Spyre Therapeutics Financial Statements
NASDAQ: SYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
85.69+5.79 (+7.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Spyre Therapeutics revenue and earnings
In fiscal 2025, Spyre Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Spyre Therapeutics reported a net loss of $155.2 million, compared with a loss of $208.0 million a year earlier.
Summary generated from market data by MetaCap's automated system. Methodology
Spyre Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 886.00K | 2.33M | 18.74M | 0 | 0 | 3.89M | 5.21M | 4.63M |
| Revenue growth (YoY) | — | -100.00% | -61.96% | -87.57% | — | — | -100.00% | -25.30% | +12.47% | — |
| Operating Expenses | 209.56M | 208.57M | 243.19M | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M |
| Research & Development | 171.65M | 162.79M | 89.50M | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M |
| Operating Income | -209.56M | -208.57M | -242.30M | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M |
| Other Income (Expense) | 54.34M | 599.00K | -96.51M | 830.00K | -11.00K | 588.00K | 2.08M | 1.11M | 440.00K | 208.00K |
| Pretax Income | -155.22M | -207.97M | -338.82M | -83.95M | -65.66M | -80.89M | -78.25M | — | — | — |
| Income Tax | -15.00K | 51.00K | -26.00K | -136.00K | 141.00K | 0 | 0 | 0 | 0 | 0 |
| Net Income | -155.20M | -208.02M | -338.79M | -83.81M | -65.80M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | 13.76 | -24.86 | -25.02 | -1.52 | -2.45 | -2.13 | -1.80 | -2.22 |
| EPS (Diluted) | — | — | 13.76 | -24.86 | -25.02 | -1.52 | -2.45 | -2.13 | -1.80 | -2.22 |
| Shares Outstanding (Basic) | — | — | 6.90M | 3.37M | 2.63M | 53.37M | 31.95M | 20.82M | 15.13M | 9.79M |
| Shares Outstanding (Diluted) | — | — | 6.90M | 3.37M | 2.63M | 53.37M | 31.95M | 20.82M | 15.13M | 9.79M |
| EBITDA | -209.56M | -208.57M | -241.56M | -83.21M | -64.07M | -80.48M | -79.92M | -45.17M | -27.43M | -21.77M |
| Operating Margin | — | — | -27347.97% | -3640.23% | -350.33% | — | — | -1169.32% | -531.72% | -473.34% |
| Net Margin | — | — | -38238.15% | -3598.75% | -351.14% | — | — | -1140.64% | -523.27% | -468.84% |
This table shows 10 annual periods of Spyre Therapeutics's income statement, from FY 2025 back to FY 2016, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SYRE's reporting calendar. What is a income statement?